Analysis Moderna Inc (MRNA)
6/4/2024
Analysis of Moderna Inc (MRNA)
Based on the provided data for Moderna Inc (MRNA) stock, here is a short analysis:1. Price Movement:
- The closing price of MRNA on June 3, 2024, was $147.82, with an opening price of $139.75. The stock reached a high of $150.80 and a low of $137.52 on that day.
2. Technical Indicators:
- Relative Strength Index (RSI): The RSI indicator on June 3 was 59.59, indicating a moderate level of buying momentum.
- Moving Average Convergence Divergence (MACD): The MACD indicator was 9.88, with the signal line at 10.34 and the histogram at -0.47. This suggests a potential bearish signal.
3. Moving Averages:
- Simple Moving Average (SMA): The SMA value was 134.37 on June 3.
- Exponential Moving Average (EMA): The EMA value was 133.94 on the same day.
- Weighted Moving Average (WMA): The WMA value stood at 139.02.
4. Overall Trend:
- The stock has been showing a mixed trend recently, with RSI indicating moderate buying momentum and MACD showing a potential bearish signal. The moving averages are also showing some variation.
5. Recommendation:
- Investors may consider monitoring the stock closely for further price movements and confirmatory signals from technical indicators before making any trading decisions.
Please note that this analysis is based on the provided data and should be supplemented with additional research and analysis for making informed investment decisions.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share (EPS), we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average EPS estimate is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. Compared to the EPS of $1.17 a year ago, there is expected growth.
2. For the next quarter ending on September 30, 2024, the average EPS estimate is higher at $1.42, ranging from $1.33 to $1.51. This indicates an improvement from the EPS of $1.35 in the same quarter last year.
3. Looking at the estimates for the current fiscal year ending on September 30, 2024, analysts project an average EPS of $6.10, with a low estimate of $5.95 and a high estimate of $6.41. This reflects growth from the EPS of $5.67 in the previous fiscal year.
4. For the next fiscal year ending on September 30, 2025, analysts anticipate further growth in EPS to an average of $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This shows an increase from the EPS of $6.10 in the current fiscal year.
Overall, the analysts' estimates suggest a positive outlook for the company's earnings per share, with expected growth in both the short term and the long term.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 38.
Overall, the analysts are generally optimistic about the company's future sales performance, with moderate to healthy growth expected in both the short term and the long term.
Growth estimates
Based on the consensus estimates provided by analysts, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is 5.2%.
3. Current Year: The estimated growth rate for the current year is 7.6%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 9.7%.
These estimates suggest that the company has been experiencing strong growth in the past, but analysts expect the growth rate to moderate slightly in the coming years, although it is still expected to be healthy.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $275
- Median: $201.43
- Average: $204.58
- Current price: $192.25
Based on these forecasts, it appears that the analysts are generally optimistic about the future price of the security, with a median forecast above the current price. However, there is a wide range between the low and high forecasts, indicating some uncertainty or differing opinions among analysts.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous results, ending on February 27, 2025, were handled by the Transfer Agent. The results from January 31, 2025, were reported after hours. The results from October 31, 2024, were not supplied at the time. The results from August 1, 2024, showed an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuations metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has a strong operating cash flow and levered free cash flow. The balance sheet shows a healthy current ratio, but a high total debt to equity ratio. The profit margin and operating margin are both positive, indicating profitability. The company's fiscal year ends in September 2023, with notable figures such as revenue, EBITDA, and net income.
Stock statistics reveal details about the company's shares, short interest, and trading volumes. The valuations metrics show various ratios like P/E, PEG, and price to book, providing insights into the company's valuation. The stock price summary includes information on beta, moving averages, and the 52-week price range.
Lastly, the dividends and splits data show the company's dividend history, payout ratio, and upcoming dividend dates. The company has a dividend yield and has undergone a stock split in the past.
Income statement 💸
These are the revenues. Here are the conclusions:1. The company's sales have been increasing steadily over the past four fiscal years.
2. The EBITDA has also shown a consistent growth trend.
3. Net income has been increasing year over year.
4. The company has been able to maintain a healthy gross profit margin.
5. Despite fluctuations in operating expenses, the company has managed to increase its operating income.
6. The basic and diluted earnings per share (EPS) have shown an upward trend.
7. The company has been able to effectively manage its income tax expenses.
8. Non-operating interest income has been relatively stable over the years.
9. The company's continuous operations have been profitable each year.
10. Overall, the financial performance of the company seems to be improving, with a focus on revenue growth and cost management.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets have fluctuated, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have shown an increasing trend, peaking at $234,386,000,000 in 2018.
4. Total liabilities have also been on the rise, with the highest value in 2018 at $255,355,000,000.
5. Shareholders' equity has generally increased, with the highest value in 2018 at $107,147,000,000.
6. The company has been investing more in non-current assets over the years.
7. There seems to be a stable increase in shareholders' equity, indicating a positive trend in the company's financial health.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company seems to be managing its cash flow effectively, with a focus on operational performance and strategic investments.
MACD of MRNA
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
